ABT
Abbott wins FDA approval of $5, 15-minute COVID test
- Abbott Laboratories (NYSE:ABT) +6.5% after-hours following news that
the FDA granted emergency use authorization for the company's 15-minute
COVID-19 test that will be priced at just $5.
- Abbott says BinaxNOW works without relying on lab equipment - at a
time when labs can take as long as two weeks to produce results - and
uses
a nasal swab and a small reactive card that can be administered by a
range
of healthcare workers, including pharmacists.
- The company plans to ship "tens of millions' of test in September,
ramping to 50M tests per month by the end of October.
- The new test "can be used at a massive scale to help overcome the
current waiting game for test results," John Hackett, divisional VP of
applied research and technology at Abbott Diagnostics, tells Bloomberg.
|Today, 7:05 PM|19 Comments
Abbott wins FDA approval of $5, 15-minute COVID test
- Abbott Laboratories (NYSE:ABT) +6.5% after-hours following news that
the FDA granted emergency use authorization for the company's 15-minute
COVID-19 test that will be priced at just $5.
- Abbott says BinaxNOW works without relying on lab equipment - at a
time when labs can take as long as two weeks to produce results - and
uses
a nasal swab and a small reactive card that can be administered by a
range
of healthcare workers, including pharmacists.
- The company plans to ship "tens of millions' of test in September,
ramping to 50M tests per month by the end of October.
- The new test "can be used at a massive scale to help overcome the
current waiting game for test results," John Hackett, divisional VP of
applied research and technology at Abbott Diagnostics, tells Bloomberg.
|Today, 7:05 PM|19 Comments
Comments
Post a Comment